The issuance of a new patent typically strengthens a company's competitive position by protecting its products from potential competitors. For Scilex, this patent for ZTlido not only enhances its intellectual property portfolio but also signals a commitment to innovation in non-opioid pain management, a significant market. This development is likely to be viewed positively by investors, as it suggests potential for sustained revenue and market share growth.